Risk Assessments: Patient Safety and Innovation Innovation Discussion 02 July 2013.

Slides:



Advertisements
Similar presentations
Disability Inclusive Disaster Risk Reduction Recommendations for Integrating the Preparedness, Response, Recovery and Mitigation Needs of the Whole Community.
Advertisements

Division: EIDD WTO TBT Workshop on Good Regulatory Practice March 2008 Focus on Transparency and Consultation.
CDCs 21 Goals. CDC Strategic Imperatives 1. Health impact focus: Align CDCs people, strategies, goals, investments & performance to maximize our impact.
Accountable Care Workgroup December 13, Agenda Call to Order/Roll Call Discussion – Discuss Key Messages/Takeaways from the Accountable Care Workgroup.
Quality Measures Vendor Tiger Team December 13, 2013.
Quality Measures Vendor Tiger Team January 30, 2014.
ELTSS Alignment to Nationwide Interoperability Roadmap DRAFT: For Stakeholder Consideration in response to public comment.
29e CONFÉRENCE INTERNATIONALE DES COMMISSAIRES À LA PROTECTION DES DONNÉES ET DE LA VIE PRIVÉE 29 th INTERNATIONAL DATA PROTECTION AND PRIVACY COMMISSIONERS.
Data-Sharing and Governance Consultation ANALYSIS OF RESPONSES.
Technology Services – National Institute of Standards and Technology The U.S. Conformity Assessment System and the Role of NIST Ileana M. Martinez National.
UC San Diego EH&S Staff Meeting Project 2010 Jan00 meeting notes.doc May 5, 2004 Update on the New Business Architecture EH&S Staff Meeting.
MEANS TO AN END: the OECD Approach for Effective Implementation of Public Procurement Systems Getting really strategic Paulo Magina Head of the Public.
ONC Policy and Program Update Health IT Standards Committee Meeting July 17, 2013 Jodi Daniel Director, Office of Policy and Planning, ONC 0.
Session 3 - Plenary on implementing Principle 1 on an Explicit Policy on Regulatory Quality, Principle 3 on Regulatory Oversight, and Principle 6 on Reviewing.
Applying the Federal Cabinet Directive on Streamlining Regulation Regulatory Craft in Nova Scotia Conference 2007 Halifax, Nova Scotia November 20, 2007.
ONC Policy and Program Update Health IT Policy Committee Meeting July 9, 2013 Jodi Daniel Director, Office of Policy and Planning, ONC 0.
Risk Assessments: Patient Safety and Innovation Innovation Discussion 18 July 2013.
ONDQA Perspective on Post Approval Changes Eric P. Duffy, PhD Director, Division of Post-Market Evaluation, ONDQA, CDER, FDA Public Meeting: Supplements.
Patient Safety Initiatives Kelly Cronin Director, Patient Safety and Outcomes Research Office of Policy and Planning Office of the Commissioner FDA.
HIT Policy Committee Accountable Care Workgroup – Kickoff Meeting May 17, :00 – 2:00 PM Eastern.
ISO Quality management International Organization for Standardization International Organization for Standardization It addresses various aspects.
FDASIA REGULATIONS SUBCOMMITTEE May 22, Agenda 4:00 p.m.Call to Order – MacKenzie Robertson Office of the National Coordinator for Health Information.
FDASIA Health IT Report Jodi G. Daniel, JD, MPH Director, Office of Policy and Planning, ONC May 6, 2014.
Risk Assessments: Patient Safety and Innovation Innovation Discussion 02 July 2013.
Work product for review and discussion by the FDASIA Regulation Subgroup; May not reflect the subgroup’s views REGULATORY WEAKNESSES A report of the typist.
Compliance and Quality Bringing It Together for Your Board Kristin Jenkins, J.D., FACHE October 2008.
A. Short term problems / considerations b. Long term mission View of human subjects protection system: SACHRP July 2008 Elizabeth Bankert.
Strategy and Innovation Workgroup May 5, 2015 David Lansky, chair Jennifer Covich, co-chair.
Risk Assessments: Patient Safety and Innovation 28 June 2013.
1 Regulatory reform, transparency and development Athens development and governance institute 21 November 2005.
Work product for review and discussion by the FDASIA Regulation Subgroup; May not reflect the subgroup’s views NEEDED REGULATORY CHANGES A report of the.
Nationwide Health Information Network: Conditions for Trusted Exchange Request For Information (RFI) Steven Posnack, MHS, MS, CISSP Director, Federal Policy.
HIT Standards Committee Privacy and Security Workgroup: Initial Reactions Dixie Baker, SAIC Steven Findlay, Consumers Union June 23, 2009.
Interoperability Framework Overview Health Information Technology (HIT) Standards Committee June 24, 2010 Presented by: Douglas Fridsma, MD, PhD Acting.
Regulation and the Governance Agenda in the 21 st Century Josef Konvitz, Public Governance Directorate.
HIT Policy Committee NHIN Workgroup Recommendations Phase 2 David Lansky, Chair Pacific Business Group on Health Danny Weitzner, Co-Chair Department of.
Protection and Prosperity Graham Russell and Ffiona Kyte, Local Better Regulation Office 21 st May 2010 Entrepreneurial Region Conference, Sweden.
1 Leveraging the WTO/TBT Agreement New Delhi, India September 11, 2008 Elise Owen Representative for China and India Affairs American National Standards.
Risk Assessments: Patient Safety and Innovation 20 May 2013.
ONC’s Proposed Strategy on Governance for the Nationwide Health Information Network Following Public Comments on RFI HIT Standards Committee Meeting September.
Catawba County Board of Commissioners Retreat June 11, 2007 It is a great time to be an innovator 2007 Technology Strategic Plan *
Work product for review and discussion by the FDASIA Regulation Subgroup; May not reflect the subgroup’s views REGULATORY WEAKNESSES A report of the typist.
Risk Assessments: Patient Safety and Innovation Paul Tang, MD Keith Larsen, RPh.
C.H. Montin, Hsin Chu, August Hsin Chu, August 2012 The OECD experience of Regulatory Policy Charles-Henri Montin, Senior Regulatory Expert, Ministry.
Better Regulation Executive Making regulation work for everyone Karen Hill Better Regulation Executive 01 March 2007 From Enforcement to Compliance: Delivering.
WHO EURO In Country Coordination and Strengthening National Interagency Coordinating Committees.
UPCOMING CHANGES TO IN-VITRO DIAGNOSTICS (IVDs) AND LABORATORY DEVELOPED TESTS (LDTs) REGULATIONS Moj Eram, PhD November 5, 2015.
MBIE Fire Programme 2015/16 Michael Belsham – Fire Engineer.
Overview of ONC Report to Congress on Health Information Blocking Presented to the Health IT Policy Committee, Task Force on Clinical, Technical, Organizational,
Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.
Subtitle Title Date Cris Ross, co-chair Anita Somplasky, co-chair January 20, 2016 Certified Technology Comparison (CTC) Task Force Final Recommendations.
An overview of OECD Strategies for Improving Regulatory Performance Regulatory Reform and Building Governance Capacities – New Delhi 3 December 2009 Mr.
Emerging SACHRP Issues K. Lynn Cates, MD Assistant Chief Research & Development Officer Director, PRIDE Office of Research & Development Department of.
Certification and Adoption Workgroup HIT Policy Committee April 28, 2014 Discussion on Incremental Rulemakings.
UCU Conference – 3 December 2009 A Presentation on the Findings of the Review of Governance in FE Allan Schofield
Examining Drug Quality Regulation Douglas C. Throckmorton, MD Deputy Director Center for Drug Evaluation and Research Public Meeting on 21 CFR February,
ACWG Charge Make recommendations to the Health IT Policy Committee on how HHS policies and programs can advance the evolution of a health IT infrastructure.
© 2011 Underwriters Laboratories Inc. Conformity Assessment Best Practices and Advancing GRP in EAC: The Value of Public-Private Partnerships EAC Workshop.
ITCILO/ACTRAV COURSE A Capacity Building for Members of Youth Committees on the Youth Employment Crisis in Africa 26 to 30 August 2013 ILO Instruments.
HIT Policy Committee Health Information Exchange Workgroup Comments on Notice of Proposed Rule Making (NPRM) and Interim Final Rule (IFR) Deven McGraw,
Final Rule Accredited Third-Party Certification 1.
IT Vendor Management March, 2015 Peter Baskette Pratike Patel.
Regulatory Updates Health Sciences Authority Singapore
Sample Fit-Gap Kick-off
Update from the Faster Payments Task Force
Successes in Achieving Health and Human Services Equity in Minnesota
Karen Proud, President Consumer Health Products Canada
Private Sector Perspective: Key “Best Practices” that Strengthen Protection of Environment, Health and Safety while Facilitating Trade and Economic Development.
FDA Sentinel Initiative
Stakeholder Engagement: Webinar Part I: The Regulatory Development Process for the Government of Canada Part II: Making Technical Regulations Under.
Presentation transcript:

Risk Assessments: Patient Safety and Innovation Innovation Discussion 02 July 2013

FDASIA Group Charter – The Food and Drug Administration Safety and Innovation Act (FDASIA) directed the HHS Secretary, acting through the Commissioner of the U.S. Food and Drug Administration (FDA), and in consultation with ONC and the Chairman of the FCC, to develop a report that contains a proposed strategy and recommendations on an appropriate, risk-based regulatory framework for health IT, including medical mobile applications, that promotes innovation, protects patient safety, and avoids regulatory duplication. – The FDA, FCC, and the HHS Office of the National Coordinator for Health IT (ONC) will review and consider the recommendations provided by the Health IT Policy Committee, based on input from the workgroup, as the three agencies write the report. Goal: recommended regulatory framework for regulation of HIT

Work Product Approaches Exam Results from Current Regulation – Experiences with current regulation – Impact on innovation Innovation Requirements – General requirements – Specific requirements - stratified by source of innovation Thoughts on new framework for innovation

IOM Report Government’s Role (IOM Report) – “The government in some cases is the only body able to provide policy guidance and direction to complement, bolster, and support private-sector efforts and to correct misaligned market forces.” Shepherding Role versus Defining or Leadership Role

Question What has been the impact of current regulatory approaches on innovation?

Regulatory Approaches Medical Device regulation Certification regulation

Nature of Innovation Risk General Attributes / Requirements IOM Report, Appendix D Stringency Innovation FlexibilityInnovation – Defined as the number of implementation paths to meet compliance.. InformationInnovation – Defined as if a regulation promotes more or less complete information in the market. Measurement Innovation Goal Attainment Specificity

Comparison of Approaches Medical Device Regulation Process control Pre-marketing approval – in some cases Impact – Can be positive when combining software from different sources – increased trust – Lack of clarity (flipside of Regulatory Discretion) yields policy uncertainty – Entry impedance Clarity on requirements & process – purpose of AAMI report Late entry into process with existing product – Continued overhead: heavy process versus agile development – If fully applied to HIT and local implementation, devastating to market – Blood Bank example – Regulatory avoidance: dis-qualify for regulatory inclusion – taxonomy discussion Certification Regulation Product definition “Best Practice” feature definitions Pre-use approval Impact – Reduced flexibility (defined features), reduced innovation – Empowered added private regulation – Non-productive work to test – “Compliance Innovation” – Less market neutral – favors existing software with defined features – Regulatory avoidance: control each features and test script

Lessons Learned Certification regimens should be avoided – They narrow creativity and innovation by either design or measurement to a specific or narrowed list of solutions – They channel energy into working to the test – compliance innovation – They channel the discussion to definitional terms rather than meeting the market needs Transparency of results to replace certification – Instead of a certification process to differentiate the market, use transparency – Transparency in the marketplace is more efficient and richer in content Certification just reveals that the system passed the certification test and all vendors will – at that point, there is no differentiation – Having a transparent, “learning system” would provide a continuous spectrum of solutions and their results; i.e., rather than knowing that all the vendors have med reconciliation (the end result of a certification system), it could be discovered which vendor does it better. National goals should be encouraged – JCAHO, Meaningful Use – They meet the “flexibility” test (Appendix D – IOM Report) – Set problem agenda, not product agenda – They do change and, if well set, correct the market and create markets – Where the market goes, vendors will follow

Questions What are the specific innovation requirements? Stratified by level of innovation or opportunity for innovation

Nature of Innovation Risk General Attributes / Requirements IOM Report, Appendix D Stringency Innovation FlexibilityInnovation – Defined as the number of implementation paths to meet compliance.. InformationInnovation – Defined as if a regulation promotes more or less complete information in the market. Measurement Innovation Goal Attainment Specificity

Summary Define process not product National and international standards for quality process – measureable and transparent National interoperability standards lower the entry cost Encourage configuration and extension to support process and solve problems Transparency of product and results Ability to experiment Local control, local accountability

Biggest picture (Regulatory Group) Looking at the three agencies together, is there a better way to regulate HIT?

Assumptions Everyone is interest in patient safety. We need innovation to solve problems in healthcare. – IT tools have a central role in solving cost and quality issues. We need to encourage more, not less, participation in this innovation and this sector.

IOM Report To encourage innovation and shared learning environments, the committee adopted the following general principles for government oversight: – Focus on shared learning, – Maximize transparency, – Be nonpunitive, – Identify appropriate levels of accountability, and – Minimize burden.

Learning Environment Requirements Increase Information in the Marketplace – Pre- and Post marketing information – Common reporting format – Providers and vendor contribution – Open access Environment – Non-punative

Comparison Current Regulation Defined solution Slow response to innovation and problems Opaque results Discourages participation Learning Environment Multiple solutions Continuous innovation Continuous measurement of results Encourages participation